Influence of comorbidity on mortality in patients with epilepsy and psychogenic nonepileptic seizures

Abstract

AbstractObjectiveThis study aims to determine the contribution of comorbidities to excess psychogenic nonepileptic seizures (PNES) mortality.MethodsA retrospective cohort study was conducted of tertiary epilepsy outpatients from St. Vincent's Hospital Melbourne, Australia with an 8:1 comparison cohort, matched by age, sex, and socioeconomic status (SES) to national administrative databases between 2007 and 2017. Privacy‐preserving data linkage was undertaken with the national prescription, National Death Index, and National Coronial Information System. Forty‐five comorbid disease classes were derived by applying the Australian validated RxRisk‐V to all dispensed prescriptions. We fitted Cox proportional hazard models controlling for age, sex, SES, comorbidity, disease duration, and number of concomitant antiseizure medications, as a marker of disease severity. We also performed a parallel forward‐selection change in estimate strategy to explore which specific comorbidities contributed to the largest changes in the hazard ratio.ResultsA total of 13 488 participants were followed for a median 3.2 years (interquartile range = 2.4–4.0 years), including 1628 tertiary epilepsy outpatients, 1384 patients with epilepsy, 176 with PNES, and 59 with both. Eighty‐two percent of epileptic seizures and 92% of typical PNES events were captured in an epilepsy monitoring unit. The age‐/sex‐/SES‐adjusted hazard ratio was elevated for epilepsy (4.74, 95% confidence interval [CI] = 3.36–6.68) and PNES (3.46, 95% CI = 1.38–8.68) and remained elevated for epilepsy (3.21, 95% CI = 2.22–4.63) but not PNES (2.15, 95% CI = .77–6.04) after comorbidity adjustment. PNES had more pre‐existing comorbidities (p = .0007), with a three times greater median weighted Rx‐RiskV score. Psychotic illness, opioid analgesia, malignancies, and nonopioid analgesia had the greatest influence on PNES comorbid risk.SignificanceHigher comorbidity appears to explain the excess PNES mortality and may represent either a wider underrecognized somatoform disorder or a psychological response to physical illness. Better understanding and management of the bidirectional relationship of these wider somatic treatments in PNES could potentially reduce the risk of death.